Arrowhead Pharmaceuticals, Inc. (ARWR) stock
ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3035% above fair value
$43.11+0.12 (+0.28%)
Close on Nov 18, 2026Market cap $6.09BP/E –Yield –
Arrowhead Pharmaceuticals pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Arrowhead Pharmaceuticals's pe ratio was 48.0× on Apr 30, 2026, against 87.1× a year earlier.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Apr 30, 2026 | 48.0× | −382.7 |
| 2020 | Jul 31, 2020 | 430.7× | +338.8 |
| 2019 | Dec 31, 2019 | 91.9× | – |
See a number that looks wrong?